AlphaGrep UK’s Gilead Sciences GILD Stock Holding History

AlphaGrep UK’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-5,212	Closed	-$658K	–	838
2026 Q2	$658K	Buy	5,212 +757	+17%	+$100K	0.2%	140
2026 Q1	$621K	Buy	4,455 +449	+11%	+$62.9K	0.18%	147
2025 Q4	$492K	Buy	+4,006	New	+$487K	0.16%	211

Other funds holding GILD

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

AlphaGrep UK's GILD Position: Q3 2026 in Review

AlphaGrep UK sold out of Gilead Sciences (GILD) in Q3 2026, closing a stake of 5,212 shares — an estimated $658K sold.

AlphaGrep UK first reported a position in GILD in Q4 2025 and held it in 3 quarters. The position peaked at $658K in Q2 2026. 2,060 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

AlphaGrep UK reported no remaining Gilead Sciences position as of Q3 2026 after selling out during the quarter.
AlphaGrep UK sold 5,212 Gilead Sciences shares in Q3 2026, an estimated $658K.
AlphaGrep UK first reported a position in Gilead Sciences in Q4 2025 and held it in 3 quarters.
AlphaGrep UK's Gilead Sciences position peaked at $658K in Q2 2026.
2,060 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on AlphaGrep UK's 13F filing for Q3 2026, filed 12 Nov 2026.